HYPERTONIA ÉS NEPHROLOGIA - eLitMed.hu
HYPERTONIA ÉS NEPHROLOGIA - eLitMed.hu
HYPERTONIA ÉS NEPHROLOGIA - eLitMed.hu
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
2002; 6 (S3): 39–46. NeoRecormon ® Quality of Life 2001 43<br />
ÖSSZEFOGLALÁS, AZ EDDIGI VIZSGÁLATOK TA-<br />
NULSÁGAI<br />
Az eddigi vizsgálatok alapján megállapíthatjuk, hogy az<br />
anaemia jelentõs rizikótényezõként szerepel az idült veseelégtelenségben<br />
jelentkezõ progresszív szívizom-hypertrophiában,<br />
valamint a dializáltak cardiovascularis halálozásában. A<br />
cardiovascularis károsodás a veseelégtelenségben korán kezdõdik.<br />
Az anaemia részleges korrekciója javítja a dializáltak<br />
túlélését, de nem normalizálja a szívelváltozásokat. A vérszegénység<br />
teljes korrekciója a szívizom kitágulását megakadályozza,<br />
de a már kialakult dilatatio, szívelégtelenség tünetei<br />
mellett további cardiovascularis elõnye jelenleg nem bizonyított.<br />
Ezek alapján az eddigi rh-EPO-kezelés stratégiájának<br />
módosítása, az anaemia korai, predialízis stádiumban történõ<br />
kezelése, megelõzése javasolt.<br />
IRODALOM<br />
1. United States Renal Data System: 1998 Annual Data Report V.<br />
Patient mortality and survival. Am J Kidney Dis 1998;<br />
32(S1):69-80.<br />
2. Charra B, Calemard E, Ruffet M, et al. Survival as an index of<br />
adequacy in dialysis. Kidney Int 1992; 41:1286-1291.<br />
3. Mátyus J, Kárpáti I, Újhelyi L. és mtsai. A hemodialízis program<br />
fejlõdése és eredményei Debrecenben 1971–1996 között. Magyar<br />
Belorv Arch 1999; 52: 237-242.<br />
4. Foley RN, Parfrey PS, Sarnak MJ. The clinical epidemiology of<br />
cardiovascular disease in chronic renal disease. Am J Kidney Dis<br />
1998; 32(S3):112-119.<br />
5. United States Renal Data System: 1998 Annual Data Report VI.<br />
Causes of death. Am J Kidney Dis 1998; 32(S1):81-88.<br />
6. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors<br />
for left ventricular disorders in chronic uraemia. Nephrol Dial<br />
Transplant 1996; 11:1277-1285<br />
7. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors<br />
of ischemic heart disease in chronic uraemia. Kidney Int 1996;<br />
49:1428-1434.<br />
8. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index<br />
increase in early renal disease: impact of decline in hemoglobin.<br />
Am J Kidney Dis 1999; 34:125-134.<br />
9. Silberberg JS, Rahal DP, Patton R, et al. Role of anaemia in the<br />
pathogenesis of left ventricular hypertrophy in end-stage renal<br />
disease. Am J Cardiol 1989; 64:222-224.<br />
10. Foley NF Parfrey PS, Harnett JD, et al. The impact of anemia on<br />
cardiomyopathy, morbidity, and mortality in end-stage renal<br />
disease. Am J Kidney Dis 1996; 28: 53-61.<br />
11. Pascual J, Teruel J.L, Moya J.L, et al. Regression of left<br />
ventricular hypertrophy after partial correction of anemia with<br />
erythropoietin in patients on hemodialysis: A prospective study.<br />
Clin Nephrol 1991; 35: 280-287.<br />
12. Locatelli F, Conte F, Marcelli D. The impact of haematocrit<br />
levels and erythropoietin treatment on overall and cardiovascular<br />
mortality and morbidity–The experience of the Lombardy<br />
Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642–<br />
1644.<br />
13. Besarab A, Bolton WK, Browne JK, et al. The effects of normál<br />
as compared with low hematocrit values in patients with cardiac<br />
disease who are receiving hemodialysis and epoetin. N Engl J<br />
Med 1998; 339: 584-590.<br />
14. Macdougall IC, Ritz E. The normal haematocrit trial in dialysis<br />
patients with cardiac disease: are we any the less confused abaut<br />
target haemoglobin? Nephrol Dial Transplant 1998; 13:3030-<br />
3033.<br />
15. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin<br />
levels in hemodialysis patients with asymptomatic cardiomyopathy.<br />
Kidney Int 2000; 58:1325-1335.<br />
16. McMahon LP, McKenna M.J, Sangkabutra T, et al. Physical<br />
performance and associated electrolyte changes after haemoglobin<br />
normalization: a comparative study in haemodialysis<br />
patients. Nephrol Dial Transplant 2000; 15:1425.<br />
17. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing<br />
the hematocrit has a beneficial effect on quality of life and is safe<br />
in selected hemodialysis patients. J Am Soc Nephrol 2000;<br />
11:335-342.<br />
18. Eckardt K-U. The CREATE trial building the evidence. Nephrol<br />
Dial Transplant 2001; 16(S2):16-18.<br />
19. Fink J, Bla<strong>hu</strong>t S, Reddy M, et al. Use of erythropoietin before the<br />
initiation of dialysis and its impact on mortality. Am J Kidney<br />
Dis 2001; 37:348-355.<br />
20. Silverberg DS, Wexler D, Blum D, et al. The use of subcutaneous<br />
erythropoietin and intravenous iron for the treatment of the<br />
anaemia of severe, resistant congestive heart failure improves<br />
cardiac and renal function and functional cardiac class, and<br />
markedly reduces hospitalizations. J Am Coll Cardiol 2000;<br />
35:1737-1744.
Change language